Forum Review Article

Oxidative Stress and Autophagy in the Regulation of Lysosome-Dependent Neuron Death

Violetta N. Pivtoraiko,¹ Sara L. Stone,¹ Kevin A. Roth,¹ and John J. Shacka^{1,2}

Abstract

Lysosomes critically regulate the pH-dependent catabolism of extracellular and intracellular macromolecules delivered from the endocytic/heterophagy and autophagy pathways, respectively. The importance of lysosomes to cell survival is underscored not only by their unique ability effectively to degrade metalloproteins and oxidatively damaged macromolecules, but also by the distinct potential for induction of both caspase-dependent and -independent cell death with a compromise in the integrity of lysosome function. Oxidative stress and free radical damage play a principal role in cell death induced by lysosome dysfunction and may be linked to several upstream and downstream stimuli, including alterations in the autophagy degradation pathway, inhibition of lysosome enzyme function, and lysosome membrane damage. Neurons are sensitive to lysosome dysfunction, and the contribution of oxidative stress and free radical damage to lysosome dysfunction may contribute to the etiology of neurodegenerative disease. This review provides a broad overview of lysosome function and explores the contribution of oxidative stress and autophagy to lysosome dysfunction-induced neuron death. Putative signaling pathways that either induce lysosome dysfunction or result from lysosome dysfunction or both, and the role of oxidative stress, free radical damage, and lysosome dysfunction in pediatric lysosomal storage disorders (neuronal ceroid lipofuscinoses or NCL/Batten disease) and in Alzheimer's disease are emphasized. *Antioxid. Redox Signal.* 11, 481–496.

Introduction

LYSOSOMES were discovered >50 years ago by Christian de Duve (41) in a series of serendipitous experiments aimed originally at characterizing liver glucose 6-phosphatase. De Duve discovered the association of glucose 6-phosphatase with a labile enzyme called acid phosphatase, which fractionated with populations of mitochondria and microsomes. On further optimization of their fractionation protocols, a "light mitochondrial" fraction was discovered that was intermediate in sedimentation to that of mitochondria and microsomes. Subsequent analysis of this purified fraction delineated several more enzymes, one of which was cathepsin D (CD), which had acid pH optima. Today the scientific community appreciates the lysosome as an organelle with the critical function of regulating the pH-dependent degra-

dation of intracellular macromolecules. The ability of lysosomes to compartmentalize degradation within their lumen protects the rest of the cell from the transient induction of oxidative stress and cytoplasmic degradation. Under conditions of cell stress, however, lysosome function and integrity may become compromised and can trigger regulated cell death. Instrumental in this cell-death induction are alterations in the vesicular recycling pathway autophagy, which can induce lysosomal dysfunction or become compromised as a result of lysosomal dysfunction or both. In addition, oxidative stress may cause direct, intralysosomal damage or cause secondary lysosomal damage through the increased production of damaged macromolecules or organelles. This review provides an overview of lysosome function and the role that oxidative stress and autophagy play in lysosomal damage. Lysosomal death pathways are explored in great

¹Department of Pathology, Neuropathology Division, University of Alabama at Birmingham, Birmingham, Alabama.

²Birmingham VA Medical Center, Birmingham, Alabama.

detail, with particular focus to their role in age-related neurodegenerative diseases including Alzheimer's disease and the pediatric neurodegenerative disease neuronal ceroid lipofuscinoses (NCL)/Batten disease.

Lysosome Structure, Function, and Assembly

Lysosomes serve an important intracellular role as the site for the terminal proteolytic degradation of damaged proteins and organelles, which is accomplished in the range of pH 4.5 to 5 *via* >50 lysosomal hydrolases with acidic pH optima (113). Morphologically, lysosomes are cytoplasmic dense bodies that are either spheroid, ovoid or occasionally tubular in appearance (113). Neuron lysosomes are typically <1 μm in size and are often situated in a perinuclear position (113). Lysosomal hydrolases are surrounded by a limiting membrane containing an abundance of glycosylated proteins (117). An intact lysosomal membrane provides the barrier necessary to maintain such a low pH compared with the neutral pH of the surrounding cytosol. Upward of two dozen cathepsins are known, with specificities for different peptide bonds, including the cysteine proteases cathepsins B (CB), H, and L or the aspartic acid protease CD. Lysosomal hydrolases catalyze the pH-dependent degradation of proteins into amino acid pools for intracellular recycling. As is discussed in subsequent sections, the increase in posttranslational oxidative modifications has been shown to decrease the effective degradation of proteins by lysosomal hydrolases and may lead to an increase in protein accumulation, which may contribute to the increase in autofluorescent lipopigment in postmitotic neurons (149).

Although lysosomal hydrolases reside at their terminal location in lysosomes, their synthesis and transport to lyso-

somes requires a complex series of events that carries them through many different organelles and vesicles (Fig. 1). Their localization to lysosomes must be confirmed either by colocalization with lysosomal membrane proteins such as LAMP-1 or LAMP-2 (49) or by subcellular fractionation. Lysosome synthesis begins initially in the endoplasmic reticulum (ER) (142), where newly synthesized hydrolases contain an N-terminal, 20- to 25-amino acid signal peptide, which allows their translocation into the ER lumen. On cleavage of the signal peptide, oligosaccharides are added onto the hydrolases, which allows the enzymes to be equipped with mannose-6-phosphate (M6P) recognition markers in the *trans* Golgi network (TGN). This M6P tag allows lysosomal hydrolases to recognize and bind to M6P receptors (M6PRs), and the receptor-ligand complex subsequently exits from the TGN in clathrin-coated vesicles as they deliver their contents directly to late endosomes or indirectly *via* delivery to early endosomes, which are thought to mature into late endosomes. Endosomes exhibit an acidic pH, as do lysosomes, but can be distinguished from lysosomes in that lysosomes are M6PR negative. The low pH of endosomes facilitates dissociation of lysosomal hydrolases from M6PRs, which allows the vesicle-mediated recycling of M6PRs back to the TGN. Concomitant with further maturation steps, including dephosphorylation, oligosaccharide trimming, and proteolytic activation, lysosomal hydrolases arrive at the lysosomes, events that are mediated most likely by a type of fusion event between the late endosome and lysosome (86).

Autophagy

Intracellular macromolecules and organelles are delivered to lysosomes for degradation and recycling by autophagy

FIG. 1. Convergence of the endosomal-lysosomal and autophagy-lysosomal degradation pathways. Lysosomal hydrolases are produced in the endoplasmic reticulum (ER) and, on delivery to the *trans*-Golgi network (TGN), are transported in vesicles by recognition of mannose-6-phosphate receptors (M6PRs) to the late endosome (or to the early endosome, which then matures to form the late endosome). The late endosome is then thought to deliver lysosomal hydrolases *via* a type of fusion event to their terminal location, the lysosome, which is M6PR negative. Damaged organelles and macromolecules are surrounded by a limiting membrane from the ER to form a preautophagosomal structure (PAS), which matures to form the double membraned autophagosome. The pH of autophagosomes is not sufficient to degrade their intraluminal contents, and fusion with lysosomes (forming the autophagolysosome) or with endosomes (forming an amphisome),

which both contain pH-dependent acid hydrolases, must take place for autophagosomal contents to be effectively degraded. Please refer to text for further details.

(Greek for “eat oneself”), and several types of autophagy dictate the manner in which macromolecules and organelles arrive at the lysosome (77). Arguably the best-studied type of autophagy is macroautophagy (Fig. 1), which involves the generation of a double-membraned autophagosome that forms nonselectively around bulk cytoplasm, and the shuttling of these contents through a series of vesicular fusion events to the lysosomes for pH-dependent degradation by lysosomal hydrolases (for review, see ref. 131). Autophagosomes may fuse with either late endosomes or lysosomes (131), which both contain lysosomal hydrolases in an acidic environment that facilitates degradation. The fusion of autophagosomes with endosomes forms single-membraned amphisomes (59, 85), which fuse ultimately with lysosomes for terminal degradation. Macroautophagy is induced by intracellular nutrient stress or energy depletion or both and is regulated at multiple levels by upward of 30 known autophagy-related gene (Atg) proteins, including signals that stimulate autophagy induction, the initiation and completion of autophagic vacuole formation, and the recycling of autophagic vacuoles (for review, see ref. 131). Chaperone-mediated autophagy (CMA) is a more-selective form of autophagy in which specific cytosolic proteins with KFERQ sequences are targeted by chaperone proteins such as hsc70 to the lysosome, followed by internalization in lysosomes by the membrane-bound, Lamp2a receptor (45). Microautophagy is a less well-defined type of autophagy in which lysosomes directly ingest cytosolic nutrients by membrane involution (158). Although microautophagy has been identified and studied in simple organisms such as yeast, its occurrence and significance in mammalian cells is unclear. Organelle-specific macroautophagy (*e.g.*, mitophagy, reticulophagy) also has been identified and may selectively target damaged organelles for lysosomal degradation (10, 76, 146). Heterophagy, by definition, is distinct from autophagy because it involves the intracellular degradation of *extracellular* material, which is mediated by endocytosis and the delivery of material to lysosomes from endosomes (120).

Redox-Reactive Iron and Intralysosomal Damage

Lysosomes play a critical role in the breakdown of iron-containing macromolecules on their delivery to lysosomes by autophagy, and as such, the lysosome contains high levels of iron (15, 111, 115, 121). Metalloproteins such as ferritin have been shown to rely on intact lysosome function for their effective degradation and removal of iron, which is thought to provide an important source of free iron for essential intracellular functions (75, 82, 111, 115). Although the compartmentalization of high concentrations of potentially redox-active iron within lysosomes is in theory a protective measure for the rest of the cell, it may also increase the susceptibility for intralysosomal damage and the induction of cell death (167). The brain and neurons, in particular, contain relatively high levels of iron, and iron has been shown to accumulate in neurons with aging (125), which further implicates the potential for iron-mediated damage in age-related neurodegenerative disease. Ferric iron (containing at least one uncoordinated ligand) may react with hydrogen peroxide in forming ferrous iron, along with the deleterious hydroxyl radical, by the Fenton reaction (81). The acidic pH of lysosomes in addition to the presence of reducing equiv-

alents such as cysteine provides a hospitable environment for Fenton chemistry (7), and hydrogen peroxide may readily diffuse into the lysosomal lumen from the cytoplasm, especially under conditions of oxidative stress. In addition, lysosomes do not ordinarily contain reducing enzymes such as catalase or glutathione peroxidase unless they are being degraded by autophagy, which exacerbates the potential for reactive iron-induced damage in lysosomes (81). Hydroxyl radical can oxidize a host of macromolecules, including lipids and proteins, which may not only inhibit their degradation and contribute to the accumulation of intralysosomal lipofuscin as discussed below, but also may inhibit the function of lysosomal hydrolases, further decreasing the degradative capacity of lysosomes (65, 133). In addition, the accumulation of oxidized lipoproteins within lysosomes may negatively affect the integrity of lysosomal membranes and provide a stimulus for the induction of lysosomal membrane permeabilization (LMP), as discussed later.

Conversely, the autophagy of thiol-rich proteins, including metallothioneins, has been proposed to counteract lysosomal damage by binding redox-active iron and other transition metals such as zinc within lysosomes, thus decreasing the probability of Fenton chemistry occurring (7, 32). In addition, under some experimental conditions, the iron chelator desferrioxamine has been shown to attenuate cell damage and cell death through its ability to localize within lysosomes and bind intralysosomal free iron (80, 109, 139, 167).

Lipofuscin and Oxidative Stress

Lipofuscin is an intralysosomal waste material that accumulates in postmitotic cells such as neurons as a function of aging, or in dividing cells whose rate of proliferation has been compromised (reviewed in ref. 17). The makeup of lipofuscin is chemically and morphologically amorphous, consisting of protein and lipid, carbohydrates, transition metals, and autofluorescent pigment (17). The accumulation of lipofuscin in postmitotic cells is closely related to a compromise in its effective degradation, combined with a lack of effective exocytosis (148). Lipofuscin accumulation is associated with age-related neurodegenerative diseases such as Alzheimer (25–27) and in lysosomal storage disorders including NCL/Batten disease (47), which may be related in part to known alterations in the macroautophagy–lysosomal degradation pathway that exist in these diseases. Whereas it is clear that lipofuscin accumulation correlates with lysosome dysfunction, it is not clear the extent to which its accumulation directly contributes to the induction of neuron death, although adverse effects on cell function have been reported (96), with an increased susceptibility of lipofuscin-loaded fibroblasts to apoptosis (147). Regardless, the finding that up to 75% of a neuron’s perikarya may contain lipofuscin [reviewed in (149)] suggests that altered lysosome function may exacerbate the sensitivity of neurons to lysosomal death signals.

The inhibition of lipofuscin degradation may result from either the inhibition of lysosomal hydrolases or an increase in oxidative stress or both. Lipofuscin accumulation has been described experimentally by the chemical inhibition of lysosomal hydrolases, either from treatment with protease inhibitors or from the lysosomotropic agent chloroquine (69,

70, 148). Age-related decreases in the activity of lysosomal hydrolases have also been documented, which may contribute to the age-related increase in lipofuscin with normal brain aging (3, 70). Conversely, the overloading of cells with lipofuscin has been shown to cause a decrease in the activity of lysosomal hydrolases (133), suggesting that lipofuscin accumulation *per se* may also initiate a compromise in lysosome function. The ability of oxidative stress to enhance lipofuscinogenesis has been documented in several cell types (137, 151, 159). Lipofuscinogenesis may be caused by proteins that are oxidatively modified outside the lysosome and subsequently delivered to lysosomes for degradation, or may be caused by the intralysosomal formation of reactive oxygen species (ROS), as suggested by the potential for lysosomal lipoproteins to acquire oxidative cross-links (16). The effect of either route would be a net increase in oxidatively modified lipofuscin, with an inherent compromise in its degradative capacity. The importance of oxidative stress in lipofuscin accumulation is further emphasized by its decrease on experimental treatment with antioxidants or the iron chelator desferrioxamine (151). In addition, the inhibition of lysosomal hydrolases may exacerbate the oxidative stress-induced accumulation of lipofuscin, because a compromise in intralysosomal enzymatic protein degradation would provide greater opportunities for such proteins to acquire oxidative modifications that contribute to lipofuscin accumulation. In support of this argument, the accumulation of lipofuscin induced by combined oxidative stress and protease inhibition was shown to be three times greater than that observed by either condition alone (148).

Lipofuscin is formed from a variety of intracellular sources that are delivered to lysosomes by the autophagy degradation pathway (for review, see ref. 131). The induction of macroautophagy may provide a potent stimulus for lipofuscin accumulation (Fig. 2). Nutrient deprivation and resultant oxidative stress are natural stimuli for macroautophagy induction, and as such, may result in the increased delivery of undegradable, oxidatively modified proteins to lysosomes that accumulate as part of lipofuscin. Along these lines, ROS induced by starvation were found recently to regulate macroautophagy induction critically through the cysteine-dependent activity of Atg4, an autophagy-specific protein that regulates autophagosome formation (124). The induction of mitophagy may also increase the lysosomal delivery of oxidatively damaged mitochondrial membranes and proteins, in addition to superoxide anion, which is generated normally in mitochondria by the electron-transport chain (37). In further support of mitophagy contributing to lipofuscin accumulation, subunit c of mitochondrial ATP synthetase has been shown to be a major component of lipofuscin, in particular in aged neurons (47). An increase in intralysosomal redox-active iron also may result from the autophagy-mediated degradation of ferritin (75, 111, 115, 121). Under conditions of oxidative stress, the diffusion of readily available hydrogen peroxide into the lysosomal lumen may drive Fenton chemistry to form the highly reactive hydroxyl radical that would promote oxidative cross-links that enhance lipofuscin accumulation, a hypothesis that has been previously proposed and is further supported by the increase in lipofuscin accumulation on inhibition of lysosomal pro-

FIG. 2. Macroautophagy induction versus inhibition in oxidative stress-induced lysosome damage. The induction of lysosomal membrane damage, LMP, and cell death may be directly influenced by both the aberrant induction and inhibition of macroautophagy, which can lead to the induction of intralysosomal oxidative stress. It has also been proposed that an initial overinduction of macroautophagy induction may lead to an eventual inhibition of macroautophagy, which also may be related in part to the induction of oxidative stress. Please see text for further details.

teases (148). The generation of intralysosomal free radicals may cause peroxidation of membrane polyunsaturated fatty acids to form relatively stable and cytotoxic aldehydes, alkenals, or hydroxyalkenals, including malondialdehyde or 4-hydroxy-nonenal (4-HNE) (50). Treatment of purified protein with 4-HNE, for instance, has been shown not only to form protein cross-links (36, 54, 156) and generate protein-associated fluorescence similar to that found in the autofluorescent lipofuscin (55, 63, 152), but also to cause enzyme inactivation (30, 38, 50, 134, 144, 156) that may further enhance lipofuscin accumulation.

Inhibition of macroautophagy completion may also contribute to the accumulation of lipofuscin (Fig. 2), as was shown previously by treatment with the lysosomotropic agent chloroquine or with protease inhibitors (69, 70, 148). Treatment with lysosomotropic agents and protease inhibitors has been shown to increase intralysosomal ferritin stability and decrease the available pools of redox-active iron (75, 82), which, in contrast to macroautophagy induction, may suggest a limited role for redox-active iron and Fenton chemistry in the intralysosomal production of ROS after macroautophagy inhibition. Rather, the inhibition of lysosomal hydrolases may initially play a more direct role in lipofuscin accumulation after macroautophagy inhibition, because in this setting, it would be logical to predict a more-direct compromise in lysosome function as the initial stimulus for altered macroautophagy. Because oxidized lipoproteins or lipofuscin accumulation has been shown experimentally to decrease the activity of lysosomal hydrolases (65, 133), it is possible that lipofuscin accumulation *per se* may also initiate a compromise in lysosome function that would lead to macroautophagy inhibition, perhaps as a response to initial macroautophagy induction. This explanation is attractive for the etiology of Alzheimer disease neuropathology, as it was hypothesized previously that macroautophagy is induced early in the course of AD onset, which is followed in later stages by macroautophagy inhibition (103, 105).

Lysosomotropic Agents Generate Oxidative Stress

Christian De Duve (42) coined the term "lysosomotropic" in 1974 to delineate a group of uncharged compounds, typically amphiphilic weak bases, that are attracted to acidic compartments within cells, or are, in other words, "acidotropic." Such uncharged molecules diffuse passively through the membranes of acidic organelles, including lysosomes, which have a typical pH range of 4.5 to 5 (106). Once inside lysosomes, these agents become protonated, and their charge effectively precludes their transport across lysosomal membranes, resulting ultimately in an effective increase in intralysosomal pH and the impairment of lysosome-mediated degradation (42, 126). Accumulation of such agents in lysosomes depends initially on the pH gradient between the intra- and extralysosomal compartments and can be prevented by the prior increase in intralysosomal pH.

Chloroquine [7-chloro-4-(4-dimethylamino-1-methylbutylamino)quinoline; see structure, Fig. 3] is a well-known antimalarial agent that has been used for many years to investigate lysosome function. Chloroquine exerts its antimalarial effects by concentrating in the acidic digestive vacuole of *Plasmodium* parasites, where it is hypothesized to complex

with ferric heme (ferriprotoporphyrin IX, FPIX) monomer (51), which is produced on parasitic degradation of host hemoglobin. By complexing with FPIX, chloroquine promotes accumulation of the toxic, undimerized form of FPIX, which increases susceptibility to iron-dependent peroxidation of lipid membranes (51), an effect that has been observed with treatment of liposomes with the chloroquine-FPIX complex (143). It is thus reasonable to predict that chloroquine also forms a similar type of lipid peroxidation-generating complex with iron-containing proteins in the lysosomes of mammalian cells. In support of this argument, chloroquine has been shown effectively to inhibit the intralysosomal release of free iron from ferritin, which is known to require intact lysosome function (75, 82). Regardless, chloroquine does induce lipid peroxidation in mammalian cells (11, 68, 112), and future studies are needed to delineate whether this occurrence is specific for lysosomal membranes. Because chloroquine effectively inhibits the intralysosomal release of free iron from ferritin, Fenton chemistry may not play a principal role in the induction of lysosomal damage mediated by chloroquine and subsequent macroautophagy inhibition.

Alternatively, chloroquine-induced oxidative damage to lysosomal membranes and the accumulation of oxidatively modified lipoproteins may result from macroautophagy inhibition combined with its inhibition of lysosomal proteases (4, 43, 53, 62, 163) mechanisms that may be responsible for its induction of lipofuscin, as previously described (70). Chloroquine also was shown recently to reduce intracellular levels of glutathione (110), which could lead to an increased production of cytosolic hydrogen peroxide and concomitant extralysosomal damage of macromolecules and organelle membranes.

The intralysosomal accumulation of chloroquine has been shown to induce profound alterations in lysosome function, including inhibition of both the proteolytic maturation and enzyme activities of CB and CD (4, 43, 53, 62, 101, 163), which may be secondary to chloroquine-induced increase in intralysosomal pH and disruption of pH optima for these enzymes. In our laboratory, we observed similar results in SH-SY5Y cells, such that a death-inducing concentration of chloroquine markedly decreases maturation of CD, as measured by Western blot (Fig. 4). However, recent reports also indicate that chloroquine increased CD levels, as measured by Western blot, but it is unclear from these studies which form of CD (pro *versus* mature, "active" forms) was increased (9, 18). Earlier studies reported an increase in lysosome size or swelling by chloroquine and other lysosomotropic agents

FIG. 3. Chemical structure of chloroquine. Chloroquine [7-chloro-4-(4-dimethylamino-1-methylbutylamino)quinoline] represents the class of fluoroquinolones.

FIG. 4. Chloroquine-induced death of human SH-SY5Y cells follows alterations in the processing of CD. (A) Treatment of human SH-SY5Y cells with chloroquine (50 μ M) significantly attenuates cell viability at 48 h *vs.* vehicle control but not at 24 h. * $p < 0.05$ *vs.* vehicle control (Student's unpaired *t* test). (B) By 24 h, chloroquine induces a modest decrease in the mature "active" form of CD, migrating at ~ 30 kDa, along with a marked increase in the inactive, "pre-pro" fragment migrating at ~ 50 kDa, in comparison to vehicle control. After 48 h of chloroquine treatment, levels of the mature active form of CD appear to be further reduced in comparison to 24 h. Levels of β -tubulin (migrating at ~ 50 kDa) serve as the loading control.

(97, 107, 138), which results from intralysosomal chloroquine reaching isotonicity with levels in the cytosol and the subsequent increase in water flow into the lysosome. Such "swollen" lysosomes may exhibit increased membrane fragility, as indicated in isolated preparations by their increased latency to release lysosomal enzymes (97, 138) by an increase in lysosomal enzymes in purified cytosolic preparations (89). These findings clearly suggest the induction of LMP and may play a significant role in the induction of cell death after chloroquine treatment, as described later.

ROS, Autophagy, and Lysosomal Membrane Permeabilizations Death Stimuli

The susceptibility of lysosomes to oxidative stress or membrane destabilization or both is thought to play a major role in the induction of LMP, which results in the release of lysosomal enzymes into the cytosol and the potent induction of cell death. Both macroautophagy induction (14, 19, 157) and

inhibition (14) have been shown to regulate cell death potentially through the induction of LMP, which may involve the generation of reactive oxygen species (Fig. 5). For many years, it was believed that LMP-induced cell death was unregulated and necrotic (40). Today, it is well established that LMP may induce both apoptosis and necrosis, which seems to depend in part on the magnitude of LMP and the amount of proteolytic enzymes released into the cytosol. Many studies have indicated that stimuli that produce LMP tend to induce apoptosis at lower concentrations and necrosis at higher concentrations (84). Because multiple types of cell death can be induced after LMP, it is not surprising that the inhibition of apoptosis after LMP has been shown to shunt the type of death to a more-necrotic nature (57). To this end, we also showed that the inhibition of Bax-dependent neuron death after lysosome dysfunction does not attenuate the degree of neuron loss or neurodegeneration (130).

The cysteine protease CB and the aspartic acid protease CD are two of the most ubiquitous lysosomal enzymes (61), and as such, they have been shown to play a major role in the stimulus-specific induction of cell death after LMP. Because lysosomal hydrolases possess optimal activation at acidic pH, it is fair to question their ability to function once released into the cytosol. However, *in vitro* studies have shown that lysosomal proteases can function for several minutes to more than an hour at neutral pH (154), confirming their potential for activation outside of lysosomes. In addition, recent studies indicated that the cytoplasmic pH is reduced in the course of cell death (98, 99), which increases the potential for lysosomal proteases directly to influence cell death after LMP.

Many studies have used hydrogen peroxide to generate oxidative stress-induced LMP and apoptosis, in both neural (21, 67) and nonneural cell types (5, 33). In addition, studies have indicated the induction of LMP by other stimuli that indirectly induce hydrogen peroxide, including TNF- α (60) and lipopolysaccharide (161). The induction of LMP by hydrogen peroxide is believed to occur through its ability to diffuse freely from the cytosol into iron-rich lysosomes, where it uses Fenton chemistry to induce the production of the highly reactive hydroxyl radical (150). In addition, both hydrogen peroxide and stimuli known to produce hydrogen peroxide indirectly (such as TNF- α) have been shown to induce activation of phospholipase A2 (PLA2), which in theory stimulates the degradation of membrane lipids that could potentially increase lysosome destabilization and LMP (71, 172). LMP-induced apoptosis has also been evidenced after treatment with other oxidative stress-inducing compounds, including naphthazarin (73), which generates ROS through redox cycling, and hypochlorous acid, shown recently to induce lysosome destabilization in cultured cortical neurons (165).

ROS-induced LMP is a potent stimulus that has been shown in many studies to precede the induction of mitochondrial-dependent apoptosis (21), which has also been indicated by treatment with lysosomotropic agents or other agents that mediate indirect production of ROS (14). In addition, several studies have shown that CB (153) and CD (74) mediate mitochondrial apoptosis, findings that strongly implicate LMP in the "lysosomal-mitochondrial axis" theory of cell death, as previously described (150). Further proof of this paradigm came from an elegant study whereby the cy-

FIG. 5. Oxidative stress, lysosomal membrane permeabilization, and the induction of necrotic versus apoptotic death. Agents that promote the direct or indirect production of oxidative stress may lead to lysosome membrane permeabilization (LMP) and cell death. It is thought that the induction of total LMP favors the onset of necrosis, whereas partial LMP favors the onset of apoptosis. LMP is associated with the release of lysosomal cathepsins into the cytosol and the interaction with pro-apoptotic Bcl-2 family members, which leads to the induction of mitochondrial apoptosis. Proapoptotic Bcl-2 family members may also act directly at the lysosomal membrane as a stimulus for LMP. For further details, please see the text.

tosolic microinjection of CD induced caspase-dependent death, an effect that was inhibited by combined microinjection of CD with its inhibitor pepstatin A (114). Conversely, lysosomal enzymes have been shown to increase production of mitochondrial ROS, which may result in further lysosomal destabilization as part of a deleterious feedback loop (171).

Recent studies have shown that one mechanism by which cytosolic cathepsins induce mitochondrial apoptosis is through direct effects on Bcl-2 family members (Fig. 5). This concept was first suggested by Stoka *et al.* (141) in 2001, which reported cleavage of the proapoptotic Bcl-2 family member Bid by lysosomal extracts, and the ability of this cleavage product to induce cytochrome *c* release from mitochondria. Bid cleavage along with induction of mitochondrial apoptosis was first shown to be mediated *via* the cysteine protease caspase-8 (83). A follow-up study confirmed that CB is directly responsible, at least in part, for Bid cleavage and induction of mitochondrial apoptosis (35). Another study suggested that CD plays a role in apoptosis mediated by Bid cleavage after treatment with ceramide (64). In addition, recent evidence has shown that after the induction of LMP, cytosolic CD interacts directly with proapoptotic Bax in the promotion of mitochondrial apoptosis by a variety of stimuli, including treatment with hydrogen peroxide (21). This CD–Bax–mitochondrial death pathway has also been shown to stimulate downstream mitochondrial release of apoptosis-inducing factor (AIF) (12),

a mitochondrial flavoprotein that, on release from mitochondria, is implicated in caspase-independent apoptosis and necrosis (39). Thus, the interaction of cytosolic cathepsins with Bcl-2 family members has the potential to induce multiple types of cell death, and future studies are warranted to determine whether this pathway also plays an important role in the induction of neuron death in acute injury or neurodegenerative disease.

For many years, it was widely believed that the regulation of cell death by Bcl-2 family members was due solely to their manipulation of mitochondrial membrane integrity. However, several intriguing studies over the last few years suggested that other organelles, including the ER and lysosomes, may also be regulated by Bcl-2 family members in the induction of cell death (61). The first reports of Bcl-2 family-mediated regulation of lysosome function were from the laboratory of Ulf Brunk (173), which suggested that lysosome-localized Bcl-2 attenuated hydrogen peroxide-induced apoptosis, at least in part, by promoting lysosome stabilization. Subsequent studies have shown that proapoptotic Bax not only localizes to lysosomal membranes after stressful stimuli but also regulates the induction of LMP (162). The BH3 domain-only molecules Bim and Bad were also shown to localize to lysosomes after a death stimulus and regulate the induction of LMP, although their induction of LMP required the presence of Bax (162). Together these findings support the potential for the additional “upstream” influence of Bcl-2 family members in the regulation of lysosome-

dependent neuron death (Fig. 5), and as a result, the potential for their regulation of multiple types of neuron death.

Chloroquine-induced Neuron Death

One of the most striking observations after treatment of cells or tissues with chloroquine is the massive accumulation of autophagic vacuoles that results from the inhibition in completion of the macroautophagy–lysosomal degradation pathway. We and others have shown that sustained incubation with chloroquine potently induces cell death that is characterized by morphologic and biochemical markers of apoptosis and is preceded by autophagic vacuole accumulation (14, 129, 168). In our laboratory, chloroquine-induced cell death has been evidenced in a variety of cell types, including immature and fully differentiated primary neurons, neural precursor cells, and a variety of neural cell lines (Fig. 4). At present, whether the accumulation of AVs directly mediates chloroquine-induced neuron death has not been thoroughly investigated, although the ability of macroautophagy inhibition to induce cell death was clearly indicated previously in the literature (14, 129). Death induced by macroautophagy inhibition may result from a compromise in homeostatic organelle turnover, thus increasing the accumulation of damaged organelles with compromised function, which could trigger the initiation or completion of death-pathway signaling. Certainly the accumulation of undegradable oxidized lipoproteins may cause associated damage to lysosomal membranes.

Mitochondrial dysfunction appears to play a major role in chloroquine-induced cell death, as indicated previously by a decrease in mitochondrial membrane potential and an attenuation of cell death by the targeted disruption of proapoptotic *bax* or *bcl-2* overexpression, and the exacerbation of cell death after the targeted disruption of antiapoptotic *bcl-x* (14, 129, 168). Although chloroquine induces robust activation of caspase-3, the targeted genetic disruption of caspase-3 or treatment with general caspase inhibitors does not attenuate chloroquine-induced neuron death (129, 168). Together, these findings suggest either that the commitment point for chloroquine-induced neuron death lies upstream of caspase activation, or indicates that the potential for both caspase-dependent and -independent death pathways triggered by disruption of the macroautophagy–lysosomal degradation pathway. We have also shown that chloroquine-induced death of immature neurons is attenuated by the protooncogene *p53*, an effect that was not observed in cultures of postmitotic neurons (68, 70), which suggests that *p53*-dependent autophagic cell death may be cell-type or differentiation dependent or both. As such, chloroquine-induced, *p53*-dependent autophagic death is being actively investigated as a potential therapeutic target in several types of cancers, including glioblastomas (110).

We showed recently that the plecomacrolide antibiotic bafilomycin A1 (BafA1) and other structurally similar compounds significantly attenuate chloroquine-induced neuron death (128, 129), at concentrations (≤ 1 nM) shown previously not to inhibit vacuolar-type ATPase (13). Although a previous study suggested that a high dose of 100 nM BafA1 attenuated cell death induced by hydroxychloroquine by attenuating the pH-dependent fusion of chloroquine into the lysosome (14), our results suggest that “neuroprotective”

concentrations of BafA1 (≤ 1 nM) do not alter the ability of chloroquine to inhibit macroautophagy, because AVs still accumulate in chloroquine+BafA1-treated cells, concomitant with an absence of apoptotic morphology, and that the chloroquine-induced inhibition of long-lived protein degradation was not affected by 1 nM BafA1 (129). Ongoing studies in our laboratory are delineating the potential mechanisms by which plecomacrolide antibiotics attenuate neuron death induced by lysosomotropic agents and whether cell death induced by other disruptions in lysosome function can also be attenuated by plecomacrolides.

Chloroquine-induced cell death was shown previously to involve LMP, as indicated immunocytochemically by the diffuse cytosolic immunoreactivity of the lysosomal protease CB in chloroquine-treated cells (14). LMP was suggested as an upstream mediator of mitochondrial cell death, because selective inhibition of CB significantly attenuated chloroquine-induced mitochondrial dysfunction concomitant with an increase in viability (14). Interestingly, chloroquine also enhances the extracellular secretion of many lysosomal enzymes, including β -hexaminodase, CB, and CD (58, 88, 100, 101, 122), which effectively blocks the delivery of newly synthesized lysosomal hydrolases to lysosomes. It will be important in future studies of chloroquine-induced LMP to confirm results of immunocytochemistry with rigorous biochemical analyses indicating an increased appearance of lysosomal enzymes in purified cytosolic fractions *via* western blot.

Chloroquine has also been shown to inhibit the activities of sphingolipid-metabolizing enzymes, including sphingomyelinase and acid ceramidase (48, 72), which are localized to lysosomes and most likely reflect the deleterious alterations in lysosome function that are induced on chloroquine treatment. Inhibition of these lipid-metabolizing enzymes causes the accumulation of ceramide and sphingosine, two highly reactive lipid mediators that have been shown to mediate oxidative stress-induced apoptosis (123, 170). Sphingosine has been shown to exhibit detergent-like properties toward lysosome membranes, which may contribute to chloroquine-induced LMP and subsequent apoptosis (74). Together, these results suggest that the aberrant production of reactive lipid metabolites not only may mediate cell death induced as a result of lysosome dysfunction mediated during macroautophagy inhibition but also may further exacerbate lysosome dysfunction and stimulate LMP-induced cell death. It should be noted, however, that inhibition of sphingolipid-metabolizing enzymes also increases levels of the antiapoptotic sphingolipid sphingosine-1-phosphate concomitant with proapoptotic sphingolipids (48), which suggests a potential balance of pro- *versus* antiapoptotic lipid mediators that must be addressed appropriately to understand the net contribution of lipid mediators in neuron death regulation.

Oxidative Stress, Autophagy, and Lysosome Dysfunction in CNS Aging and Alzheimer's Disease

Several properties of the aging brain make it uniquely susceptible to age-related oxidative damage. First, neurons are postmitotic; thus, over their life span, age-related macromolecular damage accumulates and compromises their function. This is evidenced by the age-related increase in lipo-

fuscin, which may provide both cause and effect for age-related declines in lysosome function and autophagy signaling (69, 70, 87, 149). Second, neurons have high energy demands compared with other cell types, and they may be more vulnerable to the deleterious effects of mitochondrial dysfunction, combined with the fact that the electron-transport chain of oxidative phosphorylation generates ROS (1). Third, the brain is composed of large amounts of lipids and transition metals including iron (1, 52, 169), which increases the probability of age-related lipid peroxidation. Last, the aging brain contains fewer reducing equivalents that in theory would contribute to an increase in oxidative stress (136). Age-related oxidative stress in the cytoplasm may cause macroautophagy induction, in particular as cytoplasmic macromolecules or organelles become damaged and are delivered to lysosomes for degradation. Conversely, age-related oxidative stress in the lysosome may lead to macroautophagy inhibition if the result of sustained oxidative stress is a net compromise in lysosome function.

Many studies have indicated pronounced alterations in the endosomal-lysosomal pathway in human AD brain, which are some of the earliest reported abnormalities in AD brain neurons and precede the onset of both A β -containing plaque and tangle neuropathology (28). Enlarged, A β -immunoreactive endosomes have been reported in brains of AD patients (102) before A β deposition, which suggests a potential for endosome-mediated A β secretion and deposition. Increased levels of CD have also been localized to endosomes of AD patients (23, 24). Endosomal CD may be linked to A β formation, in that CD possesses inherent β - and -secretase activity, enzymes that are responsible for the cleavage of amyloid precursor protein into A β (31), although APP processing was shown previously to be unaffected by CD deficiency in mice (119). Increased levels and activity of CB and CD in AD brain have been shown to occur concomitant with lysosome proliferation (2, 22, 24, 27, 29) and may reflect a compensatory response to altered macroautophagy, but it is not clear whether such alterations serve a beneficial role to promote protein degradation or death signaling. In addition, both CB and CD have been localized extracellularly to amyloid plaque, which may indicate their potential to regulate plaque deposition (27, 29). In support of this argument, CB has been shown effectively to decrease levels of the more amyloidogenic A β ₁₋₄₂, and CB deficiency in mice was shown to cause an increase in extracellular A β deposition (94).

Alterations in the autophagy-lysosomal degradation pathway have been indicated in AD by pathologic increases in autophagic vacuoles (AVs) observed in cortical biopsies obtained from AD brain (104, 166). Accumulating AVs in AD brain have been found to localize in large part to dystrophic neurites, which may be related to alterations in intracellular trafficking that either cause AV accumulation or result from AV accumulation. Both immature, double-membraned autophagic vacuoles and mature, single-membraned autophagolysosomes have been shown to accumulate in AD dystrophic neurites, which implicates both macroautophagy induction and inhibition in AD and may reflect both an early and late autophagic response of individual neurons to AD-associated stress. Recent evidence suggests the localization of A β in AVs both in human AD brain and in experimental models of AD, and that the processing of APP into A β may even occur within AVs (166). The intracellular accumulation

of A β has also been reported after the chemical inhibition of macroautophagy completion mediated by *in vivo* and *in vitro* treatment with chloroquine (34, 90), providing further evidence that macroautophagy plays a vital role in A β processing and degradation.

Taken together, evidence suggests that alterations in both the endosomal-lysosomal and autophagy-lysosomal degradation pathways play an intimate role in the generation of AD neuropathology, and oxidative stress may play a major role in inducing alterations in intracellular recycling pathways. Oxidative stress has been proposed to play a major role in the onset and progression of AD. Many reports of increased oxidative damage have been reported in AD brain (reviewed in refs. 20 and 92), which may have important ramifications in the macroautophagy-lysosome degradation pathway. An increase in mitophagy has been reported in AD brain (93), which is likely a response of autophagy to clear oxidatively damaged mitochondria in postmitotic neurons. Treatment of neuronal cells under conditions of oxidative stress was shown recently to induce macroautophagy of A β and promote its localization in lysosomes (174), which may reflect a stimulus early in the progression of AD to clear intracellular levels of A β . The effects of oxidative stress on lysosomal function in experimental models of AD have not been directly tested, although as described later, treatment with A β produces profound effects on lysosomal function that may be related in part to the generation of oxidative stress.

A β -Induced Neuron Death

Although it is obvious that a definite progression of neuron loss occurs in AD, studies of AD brain have in large part shown inconsistent findings regarding a role for apoptosis as an important mechanism of neuron death (reviewed in refs. 108 and 116). This variability of results may be explained by the inherent heterogeneity of the human AD population at the time of tissue biopsy and by differences in the processing of postmortem tissue. In addition, an inherent challenge exists in proving with great confidence the relevance of neuron death mechanisms in age-related neurodegenerative disease, because only a small number of neurons succumb to cell death at any one time. Nevertheless, countless studies focused on delineating the mechanisms of A β -mediated neuron death as a contributing factor to neuron loss in human AD brain.

Results of *in vitro* studies indicate a clear link between A β , oxidative stress, and cell death (reviewed in ref. 108). Many studies have shown that A β -induced cell death and apoptosis is mediated by oxidative stress (145), effects that in many cases were inhibited on treatment with antioxidants (8). Treatment with A β has been shown to increase free radical production and markers of oxidative stress (66), and the induction of oxidative stress has been shown to induce the intracellular accumulation of A β (173). As discussed earlier, the autophagy-lysosomal degradation pathway is a sensitive target for oxidative stress-induced damage, and treatment with soluble forms of A β at death-inducing concentrations has been shown to result in its intralysosomal localization (46) and induction of intralysosomal oxidative stress (46) and the induction of LMP (46). Other alterations in lysosome function, including alterations in levels of CD,

have also been reported after A β treatment (18). Although many studies of A β -induced cell death suggest a role for apoptosis (44), our laboratory previously showed that A β -induced neuron death is Bax dependent but caspase independent (127). Even though we observed activation of caspase 3 after treatment with A β , neither inhibition of caspase-3 nor the targeted genetic disruption of caspase-3 attenuated A β -induced neuron death (127). Together, these findings suggest that A β may play a significant role in oxidative stress-induced neuron death in AD brain, although the role of caspase-dependent apoptosis is still controversial. The likely disruption of the macroautophagy-lysosomal degradation pathway in AD brain, however, suggests the potential contribution of multiple types of neuron death, both caspase dependent and independent, to AD neuropathology.

Regulation of Neuron Death in CD-Deficient Mice as a Model of NCL/Batten Disease

NCL is a heterogeneous group of pediatric lysosomal storage disorders known collectively as Batten disease. Clinical features of NCL/Batten disease include seizures and progressive blindness, with eventual loss of motor control and ultimate death (56). NCLs were classified originally by their age at onset and include congenital (at birth), infantile (INCL, within 1 year of birth); late infantile (LINCL, 2–4 years); juvenile (JNCL, 4–7 years); or the very rare adult form (ANCL). Presently seven gene mutations are known in humans to cause NCL (CLN1, CLN2, CLN3, CLN5, CLN6, CLN8, and CD), which produce distinct biochemical alterations in lysosome function and are also defined by the type of storage protein that accumulates as a result of lysosome dysfunction (91).

A major focus of our laboratory is the study of CD deficiency-induced neuron death as a model of lysosome dysfunction in congenital NCL/Batten disease. It was not until 2006 that human CD mutations were first reported in two separate studies (135, 140). In one study, a complete loss of CD function was reported in four patients with congenital NCL (135), and these patients exhibited perinatal seizures before dying by 2 weeks of age. In the other study, a partial loss of CD enzymatic activity was observed in an adolescent patient diagnosed with NCL-like symptoms at early school age (135). Before the finding of CD mutations in humans, however, sporadic mutations in CD resulting in a characteristic NCL-like phenotype were reported in sheep (155) and more recently in American bulldogs (6). In 1995, the effects of experimental CD deficiency in mice were initially reported in an attempt to characterize further the role of CD in lysosome function (118). CD deficiency was found to inhibit bulk proteolysis, and CD-deficient mice died by postnatal day 26 of a plethora of morbidities including intestinal necrosis, thromboembolism, and seizures (118).

An increase in seizures and blindness in CD-deficient mice led to the subsequent analyses of brain function in these mice, when it was determined that CD deficiency resulted in robust neurodegeneration characterized by the massive accumulation of lipofuscin-laden AVs (78) and significant neuron loss (130). AVs in CD-deficient mice were found to accumulate as early as postnatal day 8 (79), and their accumulation has been shown to precede the induction of apop-

toxis (78), which occurs as early as postnatal day 16 (78). Although a role for oxidative stress has not been directly verified in the induction of AV accumulation, the accumulation of lipofuscin and likely inhibition of autophagy are strong indicators that the overproduction of oxidative stress plays a prominent role in CD deficiency-induced neuropathology, and further studies are needed to confirm this. Previous studies suggested that the induction of nitrosative stress in CD-deficient brain accelerates CD deficiency-induced neuropathology, arising potentially from an increase in nitric oxide and peroxynitrite from microglial activation (95, 164). Treatment of CD-deficient mice with inhibitors of nitric oxide synthase attenuated the appearance of apoptotic neurons but not neurons exhibiting AV accumulation and lacking apoptotic morphology (95). In particular, such apoptotic neurons were found in many cases to be localized adjacent to neurons undergoing such "autophagic stress," which led to the hypothesis that cells undergoing autophagic neurodegeneration induced microglial activation, which in turn resulted in nitric oxide-dependent apoptotic death of neighboring neurons (95). This hypothesis, if correct, would explain subsequent findings in our laboratory indicating inactivation of prosurvival Akt and activation of proapoptotic GSK-3 β in CD-deficient neurons with a time course related to that of apoptosis induction (160), along with findings in our laboratory indicating inactivation of Akt and apoptosis induction in cultured cells on treatment with peroxynitrite (132).

Further to investigate the role of apoptosis in CD deficiency-induced neuron death, we generated mice deficient in both CD and the proapoptotic molecule Bax (130). Whereas Bax deficiency clearly reduced the induction of apoptosis following CD deficiency, no decrease in neuron loss, neurodegeneration, or autofluorescent storage material was found (130). Together these results suggest that although CD deficiency induces apoptosis, the resultant lysosome dysfunction contributes to the induction of multiple types of neuron death and that apoptosis plays a limited role in the neurodegenerative phenotype induced by CD deficiency. Although the relative contribution of apoptosis to neuron death and neurodegeneration is obviously disease specific, it is clear that in the present study of neuron death, a whole host of cell-death mechanisms should be considered, including apoptotic *versus* nonapoptotic, or with different types of apoptosis that are either caspase dependent or independent.

Perspectives

Lysosome dysfunction is quickly emerging as a prominent area of research in which to study potential mechanisms of neuron death. Multiple types of neuron death delineated in the literature appear to involve, at some level, the disruption of lysosome function, and both the induction of oxidative stress and altered autophagy signaling have the capacity to regulate neuron death through the lysosome. Potential therapies such as the phosphodiesterase inhibitor zaprinast, the lysosomal "modulator" Z-Phe-Ala-diazomethylketone (PADK), plecomacrolide antibiotics such as BafA1, calpain inhibitors, cathepsin inhibitors, and metal chelators (9, 18, 33, 67, 128, 129, 165) may act through their direct attenuation of oxidative stress or indirect attenuation of oxidative stress-in-

duced damage. In theory, this would promote the stabilization of lysosome membranes and decrease the onset of LMP in neurons. The use of these agents will undoubtedly receive greater prominence in the near future as the lysosome in turn receives greater attention as a therapeutic target in the onset and progression of neurodegenerative disease.

Acknowledgments

We thank Angela Schmeckebier and Barry Bailey for expert technical assistance in preparation of the manuscript. We also thank the UAB Neuroscience Core Facilities (NS47466 and NS57098) for technical assistance. This work is supported by grants from the National Institutes of Health (NS35107 and NS41962), a pilot grant from the UAB Alzheimer's Disease Research Center, and a VISN7 Career Development Award from the Birmingham VA Medical Center.

Abbreviations

A β , beta amyloid; AD, Alzheimer disease; AIF, apoptosis-inducing factor; APP, amyloid precursor protein; Atg, autophagy-related gene; AV, autophagic vacuole; BafA1, bafilomycin A1; CB, cathepsin B; CD, cathepsin D; CMA, chaperone-mediated autophagy; ER, endoplasmic reticulum; FPIX, ferriprotoporphyrin IX; 4-HNE, 4-hydroxy-nonenal; LMP, lysosomal membrane permeabilization; M6P, mannose-6-phosphate; NCLs, neuronal ceroid lipofuscinoses; PLA2, phospholipase A2; ROS, reactive oxygen species; TGN, trans-Golgi network.

References

- Adam-Vizi V and Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. *Trends Pharmacol Sci* 27: 639–645, 2006.
- Adamec E, Mohan PS, Cataldo AM, Vonsattel JP, and Nixon RA. Up-regulation of the lysosomal system in experimental models of neuronal injury: implications for Alzheimer's disease. *Neuroscience* 100: 663–675, 2000.
- Amano T, Nakanishi H, Kondo T, Tanaka T, Oka M, and Yamamoto K. Age-related changes in cellular localization and enzymatic activities of cathepsins B, L and D in the rat trigeminal ganglion neuron. *Mech Ageing Dev* 83: 133–141, 1995.
- Ambroso JL and Harris C. Chloroquine accumulation and alterations of proteolysis and pinocytosis in the rat conceptus in vitro. *Biochem Pharmacol* 47: 679–688, 1994.
- Antunes F, Cadenas E, and Brunk UT. Apoptosis induced by exposure to a low steady-state concentration of H₂O₂ is a consequence of lysosomal rupture. *Biochem J* 356: 549–555, 2001.
- Awano T, Katz ML, O'Brien DP, Taylor JF, Evans J, Khan S, Sohar I, Lobel P, and Johnson GS. A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis. *Mol Genet Metab* 87: 341–348, 2006.
- Baird SK, Kurz T, and Brunk UT. Metallothionein protects against oxidative stress-induced lysosomal destabilization. *Biochem J* 394: 275–283, 2006.
- Behl C, Davis JB, Lesley R, and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. *Cell* 77: 817–827, 1994.
- Bendiske J and Bahr BA. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis: an approach for slowing Alzheimer disease? *J Neuropathol Exp Neurol* 62: 451–463, 2003.
- Bernales S, Schuck S, and Walter P. ER-phagy: selective autophagy of the endoplasmic reticulum. *Autophagy* 3: 285–287, 2007.
- Bhattacharyya B, Chatterjee TK, and Ghosh JJ. Effects of chloroquine on lysosomal enzymes, NADPH-induced lipid peroxidation, and antioxidant enzymes of rat retina. *Biochem Pharmacol* 32: 2965–2968, 1983.
- Bidere N, Lorenzo HK, Carmona S, Laforge M, Harper F, Dumont C, and Senik A. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. *J Biol Chem* 278: 31401–31411, 2003.
- Bowman EJ, Siebers A, and Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. *Proc Natl Acad Sci U S A* 85: 7972–7976, 1988.
- Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T, Perfettini JL, and Kroemer G. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. *Oncogene* 22: 3927–3936, 2003.
- Brun A and Brunk U. Histochemical indications for lysosomal localization of heavy metals in normal rat brain and liver. *J Histochem Cytochem* 18: 820–827, 1970.
- Brunk UT, Jones CB, and Sohal RS. A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. *Mutat Res* 275: 395–403, 1992.
- Brunk UT and Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. *Free Radic Biol Med* 33: 611–619, 2002.
- Butler D, Brown QB, Chin DJ, Batey L, Karim S, Mutneja MS, Karanian DA, and Bahr BA. Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation. *Rejuvenation Res* 8: 227–237, 2005.
- Canu N, Tufi R, Serafino AL, Amadoro G, Ciotti MT, and Calissano P. Role of the autophagic-lysosomal system on low potassium-induced apoptosis in cultured cerebellar granule cells. *J Neurochem* 92: 1228–1242, 2005.
- Castellani RJ, Honda K, Zhu X, Cash AD, Nunomura A, Perry G, and Smith MA. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. *Ageing Res Rev* 3: 319–326, 2004.
- Castino R, Bellio N, Nicotra G, Follo C, Trinchieri NF, and Isidoro C. Cathepsin D-Bax death pathway in oxidative stressed neuroblastoma cells. *Free Radic Biol Med* 42: 1305–1316, 2007.
- Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S, Lippa C, and Nixon RA. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. *Neuron* 14: 671–680, 1995.
- Cataldo AM, Barnett JL, Pieroni C, and Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. *J Neurosci* 17: 6142–6151, 1997.
- Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, and Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark

- most neurons in populations at risk to degenerate in Alzheimer's disease. *J Neurosci* 16: 186–199, 1996.
25. Cataldo AM, Hamilton DJ, and Nixon RA. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. *Brain Res* 640: 68–80, 1994.
 26. Cataldo AM and Nixon RA. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. *Proc Natl Acad Sci U S A* 87: 3861–3865, 1990.
 27. Cataldo AM, Paskevich PA, Kominami E, and Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. *Proc Natl Acad Sci U S A* 88: 10998–11002, 1991.
 28. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, and Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. *Am J Pathol* 157: 277–286, 2000.
 29. Cataldo AM, Thayer CY, Bird ED, Wheelock TR, and Nixon RA. Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin. *Brain Res* 513: 181–192, 1990.
 30. Chen JJ, Bertrand H, and Yu BP. Inhibition of adenine nucleotide translocator by lipid peroxidation products. *Free Radic Biol Med* 19: 583–590, 1995.
 31. Chevallier N, Vizzavona J, Marambaud P, Baur CP, Spillantini M, Fulcrand P, Martinez J, Goedert M, Vincent JP, and Checler F. Cathepsin D displays in vitro beta-secretase-like specificity. *Brain Res* 750: 11–19, 1997.
 32. Chimienti F, Jourdan E, Favier A, and Seve M. Zinc resistance impairs sensitivity to oxidative stress in HeLa cells: protection through metallothioneins expression. *Free Radic Biol Med* 31: 1179–1190, 2001.
 33. Choi JH, Kim DH, Yun IJ, Chang JH, Chun BG, and Choi SH. Zaprinas inhibits hydrogen peroxide-induced lysosomal destabilization and cell death in astrocytes. *Eur J Pharmacol* 571: 106–115, 2007.
 34. Chu T, Tran T, Yang F, Beech W, Cole GM, and Frautschy SA. Effect of chloroquine and leupeptin on intracellular accumulation of amyloid-beta (A β) 1–42 peptide in a murine N9 microglial cell line. *FEBS Lett* 436: 439–444, 1998.
 35. Cirman T, Oresic K, Mazovec GD, Turk V, Reed JC, Myers RM, Salvesen GS, and Turk B. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. *J Biol Chem* 279: 3578–3587, 2004.
 36. Cohn JA, Tsai L, Friguet B, and Szweda LI. Chemical characterization of a protein-4-hydroxy-2-nonenal cross-link: immunochemical detection in mitochondria exposed to oxidative stress. *Arch Biochem Biophys* 328: 158–164, 1996.
 37. Collins VP, Arborgh B, Brunk U, and Schellens JP. Phagocytosis and degradation of rat liver mitochondria by cultivated human glial cells. *Lab Invest* 42: 209–216, 1980.
 38. Dare E, Li W, Zhivotovsky B, Yuan X, and Ceccatelli S. Methylmercury and H₂O₂ provoke lysosomal damage in human astrocytoma D384 cells followed by apoptosis. *Free Radic Biol Med* 30: 1347–1356, 2001.
 39. Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Prevost MC, Leber B, Andrews D, Penninger J, and Kroemer G. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. *FASEB J* 14: 729–739, 2000.
 40. de Duve C. Lysosomes revisited. *Eur J Biochem* 137: 391–397, 1983.
 41. de Duve C. The lysosome turns fifty. *Nat Cell Biol* 7: 847–849, 2005.
 42. de Duve C, de Barse T, Poole B, Trouet A, Tulkens P, and Van Hoof F. Commentary: lysosomotropic agents. *Biochem Pharmacol* 23: 2495–2531, 1974.
 43. Decker RS, Decker ML, Thomas V, and Fuseler JW. Responses of cultured cardiac myocytes to lysosomotropic compounds and methylated amino acids. *J Cell Sci* 74: 119–135, 1985.
 44. Deshpande A, Mina E, Glabe C, and Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. *J Neurosci* 26: 6011–6018, 2006.
 45. Dice JF. Chaperone-mediated autophagy. *Autophagy* 3: 295–299, 2007.
 46. Ditaranto K, Tekirian TL, and Yang AJ. Lysosomal membrane damage in soluble A β -mediated cell death in Alzheimer's disease. *Neurobiol Dis* 8: 19–31, 2001.
 47. Elleder M, Sokolova J, and Hrebicek M. Follow-up study of subunit c of mitochondrial ATP synthase (SCMAS) in Batten disease and in unrelated lysosomal disorders. *Acta Neuropathol* 93: 379–390, 1997.
 48. Eloeimy S, Holman DH, Liu X, El Zawahry A, Villani M, Cheng JC, Mahdy A, Zeidan Y, Bielwaska A, Hannun YA, and Norris JS. New insights on the use of desipramine as an inhibitor for acid ceramidase. *FEBS Lett* 580: 4751–4756, 2006.
 49. Eskelinen EL, Tanaka Y, and Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. *Trends Cell Biol* 13: 137–145, 2003.
 50. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med* 11: 81–128, 1991.
 51. Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. *Life Sci* 74: 1957–1972, 2004.
 52. Floyd RA and Hensley K. Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. *Neurobiol Aging* 23: 795–807, 2002.
 53. Fong D and Bonner JT. Proteases in cellular slime mold development: evidence for their involvement. *Proc Natl Acad Sci U S A* 76: 6481–6485, 1979.
 54. Friguet B, Stadtman ER, and Szweda LI. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal: formation of cross-linked protein that inhibits the multicatalytic protease. *J Biol Chem* 269: 21639–21643, 1994.
 55. Friguet B, Szweda LI, and Stadtman ER. Susceptibility of glucose-6-phosphate dehydrogenase modified by 4-hydroxy-2-nonenal and metal-catalyzed oxidation to proteolysis by the multicatalytic protease. *Arch Biochem Biophys* 311: 168–173, 1994.
 56. Goebel HH and Wisniewski KE. Current state of clinical and morphological features in human NCL. *Brain Pathol* 14: 61–69, 2004.
 57. Golstein P and Kroemer G. Redundant cell death mechanisms as relics and backups. *Cell Death Differ* 12(suppl 2): 1490–1496, 2005.
 58. Gonzalez-Noriega A, Grubb JH, Talkad V, and Sly WS. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. *J Cell Biol* 85: 839–852, 1980.
 59. Gordon PB and Seglen PO. Prelysosomal convergence of autophagic and endocytic pathways. *Biochem Biophys Res Commun* 151: 40–47, 1988.

60. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, and Gores GJ. Cathepsin B contributes to TNF- α -mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. *J Clin Invest* 106: 1127–1137, 2000.
61. Guicciardi ME, Leist M, and Gores GJ. Lysosomes in cell death. *Oncogene* 23: 2881–2890, 2004.
62. Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, Isidoro C, Deture M, and Ko LW. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. *Eur J Neurosci* 27: 1119–1130, 2008.
63. Harman D. Lipofuscin and ceroid formation: the cellular recycling system. *Adv Exp Med Biol* 266: 3–15, 1989.
64. Heinrich M, Neumeyer J, Jakob M, Hallas C, Tchikov V, Winoto-Morbach S, Wickel M, Schneider-Brachert W, Trauzold A, Hethke A, and Schutze S. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. *Cell Death Differ* 11: 550–563, 2004.
65. Hoppe G, O'Neil J, and Hoff HF. Inactivation of lysosomal proteases by oxidized low density lipoprotein is partially responsible for its poor degradation by mouse peritoneal macrophages. *J Clin Invest* 94: 1506–1512, 1994.
66. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, and Bush AI. The A β peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. *Biochemistry* 38: 7609–7616, 1999.
67. Hwang JJ, Lee SJ, Kim TY, Cho JH, and Koh JY. Zinc and 4-hydroxy-2-nonenal mediate lysosomal membrane permeabilization induced by H₂O₂ in cultured hippocampal neurons. *J Neurosci* 28: 3114–3122, 2008.
68. Ivanina TA, Sakina NL, Lebedeva MN, and Borovyagin VL. A study of the mechanisms of chloroquine retinopathy. I: chloroquine effect on lipid peroxidation of retina. *Ophthalmic Res* 21: 216–220, 1989.
69. Ivy GO, Kanai S, Ohta M, Smith G, Sato Y, Kobayashi M, and Kitani K. Lipofuscin-like substances accumulate rapidly in brain, retina and internal organs with cysteine protease inhibition. *Adv Exp Med Biol* 266: 31–45, 1989.
70. Ivy GO, Schottler F, Wenzel J, Baudry M, and Lynch G. Inhibitors of lysosomal enzymes: accumulation of lipofuscin-like dense bodies in the brain. *Science* 226: 985–987, 1984.
71. Jaattela M, Benedict M, Tewari M, Shayman JA, and Dixit VM. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. *Oncogene* 10: 2297–2305, 1995.
72. Jaffrezou JP, Chen G, Duran GE, Muller C, Bordier C, Laurent G, Sikic BI, and Levade T. Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. *Biochim Biophys Acta* 1266: 1–8, 1995.
73. Kagedal K, Johansson U, and Ollinger K. The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress. *FASEB J* 15: 1592–1594, 2001.
74. Kagedal K, Zhao M, Svensson I, and Brunk UT. Sphingosine-induced apoptosis is dependent on lysosomal proteases. *Biochem J* 359: 335–343, 2001.
75. Kidane TZ, Sauble E, and Linder MC. Release of iron from ferritin requires lysosomal activity. *Am J Physiol Cell Physiol* 291: C445–C455, 2006.
76. Kim I, Rodriguez-Enriquez S, and Lemasters JJ. Selective degradation of mitochondria by mitophagy. *Arch Biochem Biophys* 462: 245–253, 2007.
77. Klionsky DJ, Cuervo AM, Dunn WA Jr, Levine B, van dK I, and Seglen PO. How shall I eat thee? *Autophagy* 3: 413–416, 2007.
78. Koike M, Nakanishi H, Saftig P, Ezaki J, Isahara K, Ohsawa Y, Schulz-Schaeffer W, Watanabe T, Waguri S, Kametaka S, Shibata M, Yamamoto K, Kominami E, Peters C, von Figura K, and Uchiyama Y. Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. *J Neurosci* 20: 6898–6906, 2000.
79. Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E, Gotow T, Peters C, von Figura K, Mizushima N, Saftig P, and Uchiyama Y. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). *Am J Pathol* 167: 1713–1728, 2005.
80. Kurz T, Gustafsson B, and Brunk UT. Intralysosomal iron chelation protects against oxidative stress-induced cellular damage. *FEBS J* 273: 3106–3117, 2006.
81. Kurz T, Terman A, and Brunk UT. Autophagy, ageing and apoptosis: the role of oxidative stress and lysosomal iron. *Arch Biochem Biophys* 462: 220–230, 2007.
82. Kwok JC and Richardson DR. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. *Mol Pharmacol* 65: 181–195, 2004.
83. Li H, Zhu H, Xu CJ, and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell* 94: 491–501, 1998.
84. Li W, Yuan X, Nordgren G, Dalen H, Dubowchik GM, Firestone RA, and Brunk UT. Induction of cell death by the lysosomotropic detergent MSDH. *FEBS Lett* 470: 35–39, 2000.
85. Liou W, Geuze HJ, Geelen MJ, and Slot JW. The autophagic and endocytic pathways converge at the nascent autophagic vacuoles. *J Cell Biol* 136: 61–70, 1997.
86. Luzio JP, Pryor PR, Gray SR, Gratian MJ, Piper RC, and Bright NA. Membrane traffic to and from lysosomes. *Biochem Soc Symp* 72: 77–86, 2005.
87. Lynch G and Bi X. Lysosomes and brain aging in mammals. *Neurochem Res* 28: 1725–1734, 2003.
88. Marquardt T, Braulke T, Hasilik A, and von Figura K. Association of the precursor of cathepsin D with coated membranes: kinetics and carbohydrate processing. *Eur J Biochem* 168: 37–42, 1987.
89. Michihara A, Toda K, Kubo T, Fujiwara Y, Akasaki K, and Tsuji H. Disruptive effect of chloroquine on lysosomes in cultured rat hepatocytes. *Biol Pharm Bull* 28: 947–951, 2005.
90. Mielke JG, Murphy MP, Maritz J, Bengualid KM, and Ivy GO. Chloroquine administration in mice increases β -amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction. *Neurosci Lett* 227: 169–172, 1997.
91. Mole SE. The genetic spectrum of human neuronal ceroid-lipofuscinoses. *Brain Pathol* 14: 70–76, 2004.
92. Moreira PI, Santos MS, Oliveira CR, Shenk JC, Nunomura A, Smith MA, Zhu X, and Perry G. Alzheimer disease and the role of free radicals in the pathogenesis of the disease. *CNS Neurol Disord Drug Targets* 7: 3–10, 2008.
93. Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szewda LI, Aliev G, Smith MA, Zhu X, and Perry G. Autophagocytosis of mitochondria is prominent in Alzheimer disease. *J Neuropathol Exp Neurol* 66: 525–532, 2007.

94. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, and Gan L. Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. *Neuron* 51: 703–714, 2006.
95. Nakanishi H, Zhang J, Koike M, Nishioku T, Okamoto Y, Kominami E, von Figura K, Peters C, Yamamoto K, Saftig P and Uchiyama Y. Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. *J Neurosci* 21: 7526–7533, 2001.
96. Neufeld EF. Lysosomal storage diseases. *Annu Rev Biochem* 60: 257–280, 1991.
97. Ngaha EO and Akanji MA. Effect of chloroquine on the stability of rat kidney lysosomes in vivo and in vitro. *Comp Biochem Physiol C* 73: 109–113, 1982.
98. Nilsson C, Johansson U, Johansson AC, Kagedal K, and Ollinger K. Cytosolic acidification and lysosomal alkalization during TNF- α induced apoptosis in U937 cells. *Apoptosis* 11: 1149–1159, 2006.
99. Nilsson C, Kagedal K, Johansson U, and Ollinger K. Analysis of cytosolic and lysosomal pH in apoptotic cells by flow cytometry. *Methods Cell Sci* 25: 185–194, 2003.
100. Nishimura Y, Amano J, Sato H, Tsuji H, and Kato K. Biosynthesis of lysosomal cathepsins B and H in cultured rat hepatocytes. *Arch Biochem Biophys* 262: 159–170, 1988.
101. Nishimura Y, Kato K, Furuno K, and Himeno M. Biosynthesis and processing of lysosomal cathepsin D in primary cultures of rat hepatocytes. *Biol Pharm Bull* 18: 825–828, 1995.
102. Nixon RA. A “protease activation cascade” in the pathogenesis of Alzheimer's disease. *Ann N Y Acad Sci* 924: 117–131, 2000.
103. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. *J Cell Sci* 120: 4081–4091, 2007.
104. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, and Cuervo AM. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. *J Neuropathol Exp Neurol* 64: 113–122, 2005.
105. Nixon RA, Yang DS, and Lee JH. Neurodegenerative lysosomal disorders: a continuum from development to late age. *Autophagy* 4: 590–599, 2008.
106. Ohkuma S and Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. *Proc Natl Acad Sci U S A* 75: 3327–3331, 1978.
107. Ohkuma S and Poole B. Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. *J Cell Biol* 90: 656–664, 1981.
108. Okouchi M, Ekshyyan O, Maracine M, and Aw TY. Neuronal apoptosis in neurodegeneration. *Antioxid Redox Signal* 9: 1059–1096, 2007.
109. Ollinger K and Brunk UT. Cellular injury induced by oxidative stress is mediated through lysosomal damage. *Free Radic Biol Med* 19: 565–574, 1995.
110. Park BC, Park SH, Paek SH, Park SY, Kwak MK, Choi HG, Yong CS, Yoo BK, and Kim JA. Chloroquine-induced nitric oxide increase and cell death is dependent on cellular GSH depletion in A172 human glioblastoma cells. *Toxicol Lett* 178: 52–60, 2008.
111. Radisky DC and Kaplan J. Iron in cytosolic ferritin can be recycled through lysosomal degradation in human fibroblasts. *Biochem J* 336: 201–205, 1998.
112. Raley MJ, Schwacha MG, and Loegering DJ. Lysosomotropic agents ameliorate macrophage dysfunction following the phagocytosis of IgG-coated erythrocytes: a role for lipid peroxidation. *Inflammation* 21: 619–628, 1997.
113. Rauch-Lüllmann Renate. History and morphology of the lysosome. In: *Lysosomes*, edited by Saftig P. New York: Springer Science+Business Media; Landes Bioscience, 2005, pp. 1–16.
114. Roberg K, Kagedal K, and Ollinger K. Microinjection of cathepsin D induces caspase-dependent apoptosis in fibroblasts. *Am J Pathol* 161: 89–96, 2002.
115. Roberts S and Bomford A. Ferritin iron kinetics and protein turnover in K562 cells. *J Biol Chem* 263: 19181–19187, 1988.
116. Roth KA. Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. *J Neuropathol Exp Neurol* 60: 829–838, 2001.
117. Saftig P. Lysosomal Membrane Proteins. In: *Lysosomes*, edited by Saftig P. New York: Springer Science+Business Media, 2005, pp. 37–49.
118. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Koster A, Hess B, Evers M, von Figura K, and Peters C. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. *EMBO J* 14: 3599–3608, 1995.
119. Saftig P, Peters C, von Figura K, Craessaerts K, Van Leuven F, and De Strooper B. Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. *J Biol Chem* 271: 27241–27244, 1996.
120. Sakai M, Araki N, and Ogawa K. Lysosomal movements during heterophagy and autophagy: with special reference to nematolysosome and wrapping lysosome. *J Electron Microscop Tech* 12: 101–131, 1989.
121. Sakaida I, Kyle ME, and Farber JL. Autophagic degradation of protein generates a pool of ferric iron required for the killing of cultured hepatocytes by an oxidative stress. *Mol Pharmacol* 37: 435–442, 1990.
122. Samarel AM, Ferguson AG, Decker RS, and Lesch M. Effects of cysteine protease inhibitors on rabbit cathepsin D maturation. *Am J Physiol* 257: C1069–C1079, 1989.
123. Sanvicens N and Cotter TG. Ceramide is the key mediator of oxidative stress-induced apoptosis in retinal photoreceptor cells. *J Neurochem* 98: 1432–1444, 2006.
124. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, and Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. *EMBO J* 26: 1749–1760, 2007.
125. Schipper HM. Brain iron deposition and the free radical-mitochondrial theory of ageing. *Ageing Res Rev* 3: 265–301, 2004.
126. Seglen PO and Gordon PB. Effects of lysosomotropic monoamines, diamines, amino alcohols, and other amino compounds on protein degradation and protein synthesis in isolated rat hepatocytes. *Mol Pharmacol* 18: 468–475, 1980.
127. Selznick LA, Zheng TS, Flavell RA, Rakic P, and Roth KA. Amyloid β -induced neuronal death is bax-dependent but caspase-independent. *J Neuropathol Exp Neurol* 59: 271–279, 2000.
128. Shacka JJ, Klocke BJ, and Roth KA. Autophagy, bafilomycin and cell death: the “a-B-cs” of plecomacrolide-induced neuroprotection. *Autophagy* 2: 228–230, 2006.
129. Shacka JJ, Klocke BJ, Shibata M, Uchiyama Y, Datta G, Schmidt RE, and Roth KA. Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. *Mol Pharmacol* 69: 1125–1136, 2006.

130. Shacka JJ, Klocke BJ, Young C, Shibata M, Olney JW, Uchiyama Y, Saftig P, and Roth KA. Cathepsin D deficiency induces persistent neurodegeneration in the absence of Bax-dependent apoptosis. *J Neurosci* 27: 2081–2090, 2007.
131. Shacka JJ, Roth KA, and Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. *Front Biosci* 13: 718–736, 2008.
132. Shacka JJ, Sahawneh MA, Gonzalez JD, Ye YZ, D'Alessandro TL, and Estevez AG. Two distinct signaling pathways regulate peroxynitrite-induced apoptosis in PC12 cells. *Cell Death Differ* 13: 1506–1514, 2006.
133. Shamsi FA and Boulton M. Inhibition of RPE lysosomal and antioxidant activity by the age pigment lipofuscin. *Invest Ophthalmol Vis Sci* 42: 3041–3046, 2001.
134. Siems WG, Hapner SJ, and van Kuijk FJ. 4-Hydroxynonenal inhibits Na(+)-K(+)-ATPase. *Free Radic Biol Med* 20: 215–223, 1996.
135. Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J, Lehesjoki AE, and Tyynela J. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. *Brain* 129: 1438–1445, 2006.
136. Sohal RS, Arnold LA, and Sohal BH. Age-related changes in antioxidant enzymes and prooxidant generation in tissues of the rat with special reference to parameters in two insect species. *Free Radic Biol Med* 9: 495–500, 1990.
137. Sohal RS, Marzabadi MR, Galaris D, and Brunk UT. Effect of ambient oxygen concentration on lipofuscin accumulation in cultured rat heart myocytes: a novel in vitro model of lipofuscinogenesis. *Free Radic Biol Med* 6: 23–30, 1989.
138. Solheim AE and Seglen PO. Structural and physical changes in lysosomes from isolated rat hepatocytes treated with methylamine. *Biochim Biophys Acta* 763: 284–291, 1983.
139. Starke PE, Gilbertson JD, and Farber JL. Lysosomal origin of the ferric iron required for cell killing by hydrogen peroxide. *Biochem Biophys Res Commun* 133: 371–379, 1985.
140. Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzer R, Bruck W, Saftig P, and Gartner J. Cathepsin D deficiency is associated with a human neurodegenerative disorder. *Am J Hum Genet* 78: 988–998, 2006.
141. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM, Bredeisen D, Freeze H, Abrahamson M, Bromme D, Krajewski S, Reed JC, Yin XM, Turk V, and Salvesen GS. Lysosomal protease pathways to apoptosis: cleavage of bid, not pro-caspases, is the most likely route. *J Biol Chem* 276: 3149–3157, 2001.
142. Storch S and Bräulke T. Transport of lysosomal enzymes. In *Lysosomes*, edited by Saftig P. New York: Springer Science+Business Media; Landes Bioscience, 2005, pp. 17–26.
143. Sugioka Y, Suzuki M, Sugioka K, and Nakano M. A ferriprotoporphyrin IX-chloroquine complex promotes membrane phospholipid peroxidation: a possible mechanism for antimalarial action. *FEBS Lett* 223: 251–254, 1987.
144. Szweda LI, Uchida K, Tsai L, and Stadtman ER. Inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal: selective modification of an active-site lysine. *J Biol Chem* 268: 3342–3347, 1993.
145. Tamagno E, Parola M, Guglielmotto M, Santoro G, Bardini P, Marra L, Tabaton M, and Danni O. Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. *Free Radic Biol Med* 35: 45–58, 2003.
146. Tasdemir E, Maiuri MC, Tajeddine N, Vitale I, Ciriello A, Vicencio JM, Hickman JA, Geneste O, and Kroemer G. Cell cycle-dependent induction of autophagy, mitophagy and reticulophagy. *Cell Cycle* 6: 2263–2267, 2007.
147. Terman A, Abrahamsson N, and Brunk UT. Ceroid/lipofuscin-loaded human fibroblasts show increased susceptibility to oxidative stress. *Exp Gerontol* 34: 755–770, 1999.
148. Terman A and Brunk UT. Ceroid/lipofuscin formation in cultured human fibroblasts: the role of oxidative stress and lysosomal proteolysis. *Mech Ageing Dev* 104: 277–291, 1998.
149. Terman A and Brunk UT. Lipofuscin: mechanisms of formation and increase with age. *APMIS* 106: 265–276, 1998.
150. Terman A, Gustafsson B, and Brunk UT. The lysosomal-mitochondrial axis theory of postmitotic aging and cell death. *Chem Biol Interact* 163: 29–37, 2006.
151. Thaw HH, Collins VP, and Brunk UT. Influence of oxygen tension, pro-oxidants and antioxidants on the formation of lipid peroxidation products (lipofuscin) in individual cultivated human glial cells. *Mech Ageing Dev* 24: 211–223, 1984.
152. Tsai L, Szweda PA, Vinogradova O, and Szweda LI. Structural characterization and immunochemical detection of a fluorophore derived from 4-hydroxy-2-nonenal and lysine. *Proc Natl Acad Sci U S A* 95: 7975–7980, 1998.
153. Tsuchiya K, Kohda Y, Yoshida M, Zhao L, Ueno T, Yamashita J, Yoshioka T, Kominami E, and Yamashita T. Postictal blockade of ischemic hippocampal neuronal death in primates using selective cathepsin inhibitors. *Exp Neurol* 155: 187–194, 1999.
154. Turk B, Dolenc I, Turk V, and Bieth JG. Kinetics of the pH-induced inactivation of human cathepsin L. *Biochemistry* 32: 375–380, 1993.
155. Tyynela J, Sohar I, Sleat DE, Gin RM, Donnelly RJ, Baumann M, Haltia M, and Lobel P. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. *EMBO J* 19: 2786–2792, 2000.
156. Uchida K and Stadtman ER. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase: a possible involvement of intra- and intermolecular cross-linking reaction. *J Biol Chem* 268: 6388–6393, 1993.
157. Uchiyama Y. Autophagic cell death and its execution by lysosomal cathepsins. *Arch Histol Cytol* 64: 233–246, 2001.
158. Uttenweiler A and Mayer A. Microautophagy in the yeast *Saccharomyces cerevisiae*. *Methods Mol Biol* 445: 245–259, 2008.
159. Von Zglinicki T, Nilsson E, Docke WD, and Brunk UT. Lipofuscin accumulation and ageing of fibroblasts. *Gerontology* 41(suppl 2): 95–108, 1995.
160. Walls KC, Klocke BJ, Saftig P, Shibata M, Uchiyama Y, Roth KA, and Shacka JJ. Altered regulation of phosphatidylinositol 3-kinase signaling in cathepsin D-deficient brain. *Autophagy* 3: 222–229, 2007.
161. Wang JH, Redmond HP, Watson RW, and Bouchier-Hayes D. Induction of human endothelial cell apoptosis requires both heat shock and oxidative stress responses. *Am J Physiol* 272: C1543–C1551, 1997.
162. Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, and Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. *J Biol Chem* 282: 28960–28970, 2007.
163. Wibo M and Poole B. Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. *J Cell Biol* 63: 430–440, 1974.
164. Yamasaki R, Zhang J, Koshiishi I, Sastradipura Suniarti DF, Wu Z, Peters C, Schwake M, Uchiyama Y, Kira J, Saftig P,

- Utsumi H, and Nakanishi H. Involvement of lysosomal storage-induced p38 MAP kinase activation in the overproduction of nitric oxide by microglia in cathepsin D-deficient mice. *Mol Cell Neurosci* 35: 573–584, 2007.
165. Yap YW, Whiteman M, Bay BH, Li Y, Sheu FS, Qi RZ, Tan CH, and Cheung NS. Hypochlorous acid induces apoptosis of cultured cortical neurons through activation of calpains and rupture of lysosomes. *J Neurochem* 98: 1597–1609, 2006.
 166. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Naslund J, Mathews PM, Cataldo AM, and Nixon RA. Macroautophagy: a novel beta-amyloid peptide-generating pathway activated in Alzheimer's disease. *J Cell Biol* 171: 87–98, 2005.
 167. Yu Z, Persson HL, Eaton JW, and Brunk UT. Intralysosomal iron: a major determinant of oxidant-induced cell death. *Free Radic Biol Med* 34: 1243–1252, 2003.
 168. Zaidi AU, McDonough JS, Klocke BJ, Latham CB, Korsmeyer SJ, Flavell RA, Schmidt RE, and Roth KA. Chloroquine-induced neuronal cell death is p53 and Bcl-2 family-dependent but caspase-independent. *J Neuropathol Exp Neurol* 60: 937–945, 2001.
 169. Zecca L, Youdim MB, Riederer P, Connor JR, and Crichton RR. Iron, brain ageing and neurodegenerative disorders. *Nat Rev Neurosci* 5: 863–873, 2004.
 170. Zhao H, Cai Y, Santi S, Lafrenie R, and Lee H. Chloroquine-mediated radiosensitization is due to the destabilization of the lysosomal membrane and subsequent induction of cell death by necrosis. *Radiat Res* 164: 250–257, 2005.
 171. Zhao M, Antunes F, Eaton JW, and Brunk UT. Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. *Eur J Biochem* 270: 3778–3786, 2003.
 172. Zhao M, Brunk UT, and Eaton JW. Delayed oxidant-induced cell death involves activation of phospholipase A2. *FEBS Lett* 509: 399–404, 2001.
 173. Zhao M, Eaton JW, and Brunk UT. Bcl-2 phosphorylation is required for inhibition of oxidative stress-induced lysosomal leak and ensuing apoptosis. *FEBS Lett* 509: 405–412, 2001.
 174. Zheng L, Roberg K, Jerhammar F, Marcusson J, and Terman A. Autophagy of amyloid beta-protein in differentiated neuroblastoma cells exposed to oxidative stress. *Neurosci Lett* 394: 184–189, 2006.

Address reprint requests to:
 John J. Shacka
 SC 843A
 1530 3rd Ave S
 Birmingham, AL 35294-0017

E-mail: shacka@uab.edu

Date of first submission to ARS Central, August 25, 2008;
 date of acceptance, August 28, 2008.